The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Vascular Endothelial Growth Factor Affects Dendritic Cell Maturation Through the Inhibition of Nuclear Factor-κB Activation in Hemopoietic Progenitor Cells
Abstract
Vascular endothelial growth factor (VEGF), produced by almost all tumor cells, affects the ability of hemopoietic progenitor cells (HPC) to differentiate into functional dendritic cells (DC) during the early stages of their maturation. In this study we demonstrate specific binding of VEGF to HPC. This binding was efficiently competed by placenta growth factor (PlGF), a ligand reportedly specific for the Flt-1 receptor. The number of binding sites for VEGF decreased during DC maturation in vitro associated with decreased levels of mRNA for Flt-1. VEGF significantly inhibited nuclear factor-κB (NF-κB)-dependent activation of reporter gene transcription during the first 24 h in culture. The presence of VEGF significantly decreased the specific DNA binding of NF-κB as early as 30 min after induction with TNF-α. This was followed on days 7 to 10 by decreases in the mRNA for RelB and c-Rel, two subunits of NF-κB. Blockade of NF-κB activity in HPC at early stages of differentiation with an adenovirus expressing a dominant IκB inhibitor of NF-κB reproduced the pattern of effects observed with VEGF. Thus, NF-κB plays an important role in maturation of HPCs to DC, and VEGF activation of the Flt-1 receptor is able to block the activation of NF-κB in this system. Blockade of NF-κB activation in HPCs by tumor-derived factors may therefore be a mechanism by which tumor cells can directly down-modulate the ability of the immune system to generate effective antitumor immune responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
THE ATTRACTIONS OF PROTEINS FOR SMALL MOLECULES AND IONS
Scatchard, G. (1949) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1949.tb27297.x · Cited by 19,778
Dudley, R. K. (1988) · FEBS Letters · doi:10.1016/0014-5793(88)80264-3 · Cited by 5,945
Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V., & Ferrara, N. (1989) · Science · doi:10.1126/science.2479986 · Cited by 4,986
The fms -Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor
de Vries, C., Escobedo, J. A., Ueno, H., Houck, K., Ferrara, N., & Williams, L. T. (1992) · Science · doi:10.1126/science.1312256 · Cited by 2,016
Inducibility of κ immunoglobulin enhancer-binding protein NF-κB by a posttranslational mechanism
Sen, R., & Baltimore, D. (1986) · Cell · doi:10.1016/0092-8674(86)90807-x · Cited by 1,993
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Self-citationProliferating dendritic cell progenitors in human blood.
Romani, N., Gruner, S., Brang, D., Kämpgen, E., Lenz, A., Trockenbacher, B., Konwalinka, G., Fritsch, P. O., Steinman, R. M., & Schuler, G. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.1.83 · Cited by 1,840
Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation.
Verma, I. M., Stevenson, J. K., Schwarz, E. M., Van Antwerp, D., & Miyamoto, S. (1995) · Genes & Development · doi:10.1101/gad.9.22.2723 · Cited by 1,724
Waltenberger, J., Claesson-Welsh, L., Siegbahn, A., Shibuya, M., & Heldin, C. H. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47116-5 · Cited by 1,656
Molecular and Biological Properties of the Vascular Endothelial Growth Factor Family of Proteins
FERRARA, N., HOUCK, K., JAKEMAN, L., & LEUNG, D. W. (1992) · Endocrine Reviews · doi:10.1210/edrv-13-1-18 · Cited by 1,655
Cited by
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
Top 10 Challenges in Cancer Immunotherapy
Hegde, P. S., & Chen, D. S. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.011 · Cited by 2,238
Mao, X., Xu, J., Wang, W., Liang, C., Hua, J., Liu, J., Zhang, B., Meng, Q., Yu, X., & Shi, S. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01428-1 · Cited by 2,290
Vascular Endothelial Growth Factor and Angiogenesis
Hoeben, A., Landuyt, B., Highley, M. S., Wildiers, H., Van Oosterom, A. T., & De Bruijn, E. A. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.4.3 · Cited by 1,824
Toward personalized treatment approaches for non-small-cell lung cancer
Wang, M., Herbst, R. S., & Boshoff, C. (2021) · Nature Medicine · doi:10.1038/s41591-021-01450-2 · Cited by 1,093
Cancer immunoediting from immune surveillance to immune escape
Kim, R., Emi, M., & Tanabe, K. (2007) · Immunology · doi:10.1111/j.1365-2567.2007.02587.x · Cited by 1,074
Natural selection of tumor variants in the generation of “tumor escape” phenotypes
Khong, H. T., & Restifo, N. P. (2002) · Nature Immunology · doi:10.1038/ni1102-999 · Cited by 1,058
Mechanisms and functional significance of tumour-induced dendritic-cell defects
Gabrilovich, D. (2004) · Nature Reviews Immunology · doi:10.1038/nri1498 · Cited by 1,024
Self-citationRini, B. I., Powles, T., Atkins, M. B., Escudier, B., McDermott, D. F., Suarez, C., Bracarda, S., Stadler, W. M., Donskov, F., Lee, J. L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30723-8 · Cited by 994
Gabrilovich, D., Ishida, T., Oyama, T., Ran, S., Kravtsov, V., Nadaf, S., & Carbone, D. P. (1998) · Blood · doi:10.1182/blood.v92.11.4150 · Cited by 1,048
Self-citationTreatment of renal cell carcinoma: Current status and future directions
Barata, P. C., & Rini, B. I. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21411 · Cited by 831
Role of vascular endothelial growth factor in the regulation of angiogenesis
Ferrara, N. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00610.x · Cited by 731
Rodríguez, P. C., & Ochoa, A. C. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00608.x · Cited by 719
Lee, W. S., Yang, H., Chon, H. J., & Kim, C. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00500-y · Cited by 688
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
Khan, K. A., & Kerbel, R. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.9 · Cited by 657
Combination strategies to maximize the benefits of cancer immunotherapy
Zhu, S., Zhang, T., Zheng, L., Liu, H., Song, W., Liu, D., Li, Z., & Pan, C.-X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01164-5 · Cited by 654
Targeting VEGF/VEGFR to modulate antitumor immunity
Yang, J., Yan, J., & Liu, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00978 · Cited by 646
Secretion of immunoregulatory cytokines by mesenchymal stem cells
Kyurkchiev, D. (2014) · World Journal of Stem Cells · doi:10.4252/wjsc.v6.i5.552 · Cited by 617
Bevacizumab plus ipilimumab in patients with metastatic melanoma
Hodi, F. S., Lawrence, D., Lezcano, C., Wu, X., Zhou, J., Sasada, T., Zeng, W., Giobbie-Hurder, A., Atkins, M. B., Ibrahim, N., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0053 · Cited by 593
“VEGF has profound effects on immune regulatory cell function, specifically inhibiting dendritic cell maturation and antigen presentation (3,4).”
BackgroundDuluc, D., Delneste, Y., Tan, F., Moles, M.-P., Grimaud, L., Lenoir, J., Preisser, L., Anegon, I., Catala, L., Ifrah, N., et al. (2007) · Blood · doi:10.1182/blood-2007-02-072587 · Cited by 491
The Intersection between Tumor Angiogenesis and Immune Suppression
Rahma, O. E., & Hodi, F. S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1543 · Cited by 472
Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer
Nefedova, Y., Huang, M., Kusmartsev, S., Bhattacharya, R., Cheng, P., Salup, R., Jove, R., & Gabrilovich, D. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.1.464 · Cited by 464
Self-citationThe TRAF Family of Signal Transducers Mediates NF-κB Activation by the TRANCE Receptor
Wong, B. R., Josien, R., Lee, S. Y., Vologodskaia, M., Steinman, R. M., & Choi, Y. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.43.28355 · Cited by 458
Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics
Hegde, P. S., Wallin, J. J., & Mancao, C. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.12.002 · Cited by 453
Nuclear transcription factor-κB as a target for cancer drug development
Garg, A., & Aggarwal, B. (2002) · Leukemia · doi:10.1038/sj.leu.2402482 · Cited by 441
Anti-angiogenic therapy: current challenges and future perspectives
Lopes-Coelho, F., Martins, F., Pereira, S. A., & Serpa, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073765 · Cited by 416
Podar, K., Tai, Y.-T., Davies, F. E., Lentzsch, S., Sattler, M., Hideshima, T., Lin, B. K., Gupta, D., Shima, Y., Chauhan, D., et al. (2001) · Blood · doi:10.1182/blood.v98.2.428 · Cited by 415
Cytokines in cancer immunity and immunotherapy
Smyth, M. J., Cretney, E., Kershaw, M. H., & Hayakawa, Y. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00199.x · Cited by 412
Ugurel, S., Rappl, G., Tilgen, W., & Reinhold, U. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.577 · Cited by 399
Immature, but not inactive: the tolerogenic function of immature dendritic cells
Mahnke, K., Schmitt, E., Bonifaz, L., Enk, A. H., & Jonuleit, H. (2002) · Immunology & Cell Biology · doi:10.1046/j.1440-1711.2002.01115.x · Cited by 384
Alteration of the Antitumor Immune Response by Cancer-Associated Fibroblasts
Ziani, L., Chouaib, S., & Thiery, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00414 · Cited by 381
Sarris, M., Andersen, K. G., Randow, F., Mayr, L., & Betz, A. G. (2008) · Immunity · doi:10.1016/j.immuni.2008.01.012 · Cited by 359
Bellamy, W. T., Richter, L., Sirjani, D., Roxas, C., Glinsmann-Gibson, B., Frutiger, Y., Grogan, T. M., & List, A. F. (2001) · Blood · doi:10.1182/blood.v97.5.1427 · Cited by 342
Dendritic cell dysfunction in cancer: A mechanism for immunosuppression
Pinzon‐Charry, A., Maxwell, T., & López, J. A. (2005) · Immunology & Cell Biology · doi:10.1111/j.1440-1711.2005.01371.x · Cited by 328
Control of the Immune Response by Pro-Angiogenic Factors
Voron, T., Marcheteau, E., Pernot, S., Colussi, O., Tartour, E., Taieb, J., & Terme, M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00070 · Cited by 325
Raber, P., Ochoa, A. C., & Rodríguez, P. C. (2012) · Immunological Investigations · doi:10.3109/08820139.2012.680634 · Cited by 322
Tartour, E., Pere, H., Maillere, B., Terme, M., Merillon, N., Taieb, J., Sandoval, F., Quintin-Colonna, F., Lacerda, K., Karadimou, A., et al. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9281-4 · Cited by 316
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients
Osada, T., Chong, G., Tansik, R., Hong, T., Spector, N., Kumar, R., Hurwitz, H. I., Dev, I., Nixon, A. B., Lyerly, H. K., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0441-x · Cited by 311
Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy
Ciardiello, D., Vitiello, P. P., Cardone, C., Martini, G., Troiani, T., Martinelli, E., & Ciardiello, F. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.04.003 · Cited by 304
Keilholz, U., Weber, J., Finke, J. H., Gabrilovich, D. I., Kast, W. M., Disis, M. L., Kirkwood, J. M., Scheibenbogen, C., Schlom, J., Maino, V. C., et al. (2002) · Journal of Immunotherapy · doi:10.1097/00002371-200203000-00001 · Cited by 298
Self-citationMelani, C., Chiodoni, C., Forni, G., & Colombo, M. P. (2003) · Blood · doi:10.1182/blood-2003-01-0190 · Cited by 295
Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species
Kusmartsev, S., & Gabrilovich, D. I. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0103010 · Cited by 292
Self-citationArginine Metabolism in Myeloid Cells Shapes Innate and Adaptive Immunity
Rodriguez, P. C., Ochoa, A. C., & Al-Khami, A. A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00093 · Cited by 285
Vermaelen, K., & Pauwels, R. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200410-1384so · Cited by 283
Dendritic cells: regulators of alloimmunity and opportunities for tolerance induction
Morelli, A. E., & Thomson, A. W. (2003) · Immunological Reviews · doi:10.1046/j.1600-065x.2003.00079.x · Cited by 283
Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors
Muller, A. J., & Scherle, P. A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1929 · Cited by 262
Dendritic Cell-Based Xenoantigen Vaccination for Prostate Cancer Immunotherapy
Fong, L., Brockstedt, D., Benike, C., Breen, J. K., Strang, G., Ruegg, C. L., & Engleman, E. G. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.12.7150 · Cited by 252
Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy
Wu, X., Giobbie-Hurder, A., Liao, X., Connelly, C., Connolly, E. M., Li, J., Manos, M. P., Lawrence, D., McDermott, D., Severgnini, M., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0206 · Cited by 164
Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08.
Pogue-Geile, K., Yothers, G., Taniyama, Y., Tanaka, N., Gavin, P., Colangelo, L., Blackmon, N., Lipchik, C., Kim, S. R., Sharif, S., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt140 · Cited by 61
Napoletano, C., Ruscito, I., Bellati, F., Zizzari, I. G., Rahimi, H., Gasparri, M. L., Antonilli, M., Panici, P. B., Rughetti, A., & Nuti, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8030380 · Cited by 43
Jeong, B.-E., Ko, E.-J., & Joo, H.-G. (2012) · Food and Chemical Toxicology · doi:10.1016/j.fct.2012.01.034 · Cited by 39
Zhou, Y., Li, M., Zhang, B., Yang, C., Wang, Y., Zheng, S., Tang, L., Zhou, C., Qian, G., Huang, Y., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-03132-x · Cited by 22
Recruiting Immunity for the Fight against Colorectal Cancer: Current Status and Challenges
Al-Hujaily, E. M., Al-Sowayan, B. S., Alyousef, Z., Uddin, S., & Alammari, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213696 · Cited by 6
Metadata
- Authors
- Oyama, T., Ran, S., Ishida, T., Nadaf, S., Kerr, L., Carbone, D. P., & Gabrilovich, D. I.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1998-02-01
- Volume
- 160
- Issue
- 3
- Pages
- 1224-1232
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W4313333674
- Cited by
- 481
- References
- 46
- FWCI
- 3.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.